Resveratrol reversed arterial stiffness in patients with type 2 diabetes, according to an abstract presented at the American Heart Association’s Arteriosclerosis, Thrombosis and Vascular Biology/Peripheral Vascular Disease Scientific Sessions.
“This adds to emerging evidence that there may be interventions that may reverse the blood vessel abnormalities that occur with aging and are more pronounced in people with type 2 diabetes and obesity,” Naomi M. Hamburg, MD, MS, FACC, associate professor of medicine and chief of the vascular biology section at the Boston University School of Medicine, said in a press release.
Naomi M. Hamburg
Carotid-femoral pulse wave velocity was numerically lower in the resveratrol group (P = .18) compared with those assigned placebo. Patients with high arterial stiffness at the start of the study (n = 23) experienced reduced carotid-femoral pulse wave velocity without altering systemic BP when taking resveratrol 300 mg (9.1%) and resveratrol 100 mg (4.8%), whereas stiffness in the placebo group increased.
Researchers collected venous endothelial cells from seven patients assigned resveratrol and discovered increased SIRT1 activity, which may underlie the arterial stiffening reversal in the resveratrol group.
Hamburg and colleagues did not observe any effect of resveratrol on brachial artery flow-mediated dilation, reactive hyperemia or pulse amplitude tonometry.
“We found that resveratrol also activates the longevity gene SIRT1 in humans, and this may be a potential mechanism for the supplements to reduce aortic stiffness,” Ji-Yao Ella Zhang, PhD, postdoctoral fellow at Boston University Whitaker Cardiovascular Institute, said in the release. “However, the changes in this small and short-term study are not proof. Studies with longer treatment are needed to test the effects of a daily resveratrol supplement on vascular function.” – by Darlene Dobkowski
Zhang J, et al. Poster 164. Presented at: American Heart Association’s Arteriosclerosis, Thrombosis and Vascular Biology | Peripheral Vascular Disease Scientific Sessions; May 4-6, 2017; Minneapolis.
The researchers report no relevant financial disclosures.